Zobrazeno 1 - 10
of 26
pro vyhledávání: ''
Autor:
Charles Jeng Chen, Terrence Bradley, Helena G. Dos Santos, Ronan T. Swords, Luisa Cimmino, Yvonne Trang Dinh, Ramin Shiekhattar, Artur Zelent, Justin M. Watts, Aymee Perez, Deukwoo Kwon, Mina Masoumeh Tayari, Amber Thomassen, Lluis Morey
Publikováno v:
Clin Cancer Res
Purpose: In preclinical studies, the lysine-specific histone demethylase 1A (LSD1) inhibitor tranylcypromine (TCP) combined with all-trans retinoic acid (ATRA) induces differentiation and impairs survival of myeloid blasts in non-acute promyelocytic
Autor:
Julie Roques, Patricia Santofimia-Castaño, Analía Meilerman Abuelafia, Odile Gayet, Emmanuel Telle, Juan L. Iovanna, Nicolas A. Fraunhoffer, Maria Teresa Borrello, Nelson Dusetti, Martin Bigonnet, Eduardo Chuluyan
Publikováno v:
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a survival rate less than 5%. Multiple chemotherapeutic drugs have been tested to improve patient prognosis; however, the clinical efficacy of these treatments is low. One of th
Autor:
Charalambos Andreadis, Scott Thomas, McNancy Kang, Aaron C Logan, Matthew J. Wieduwilt, Nela Pawlowska, Karin M.L. Gaensler, Pamela N. Munster, Thomas Martin, Wanda Boyer, Peter H. Sayre, Lloyd E. Damon, Rebecca L. Olin, Kirsten Anderson
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(16)
Purpose: The histone deacetylase (HDAC) inhibitor panobinostat potentiates anthracycline and cytarabine cytotoxicity in acute myeloid leukemia (AML) cells. We hypothesized that panobinostat prior to and during induction chemotherapy would be tolerabl
Autor:
Anne Gompel, Pierre-Alexandre Just, Bruno Borghese, Patricia Forgez, Zherui Wu, Joël Poupon, Jin Liu, Evelyne Ségal-Bendirdjian, M. Agopiantz, Guillaume Gauchotte
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(21)
Purpose: The high affinity receptor 1 (NTSR1) and its agonist, neurotensin (NTS), are correlated with tumor cell aggressiveness in most solid tumors. As chemoresistance and tumor aggressiveness are often related, we decided to study the role of the N
Autor:
Robert J. Kinders, Maria R. Baer, Steven D. Gore, Douglas E. Gladstone, James G. Herman, Ivana Gojo, Amy E. DeZern, Larry M. Karnitz, Scott H. Kaufmann, Lihua Wang, Hetty E. Carraway, Judith E. Karp, Michelle A. Rudek, Michael A. McDevitt, Margaret M. Showel, Ismail Ali-Walbi, Amanda L. Blackford, Mark J. Levis, Marie Pouquet, Jan H. Beumer, Weijie Poh, B. Douglas Smith, Keith W. Pratz, Jiuping Jay Ji, Alice P. Chen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(3)
Purpose: In preclinical studies, the PARP inhibitor veliparib enhanced the antileukemic action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a phase 1 study of temozolomide with escalating doses of veliparib in patient
Autor:
Christoph C. Zielinski, Oliver Königsbrügge, Gerhard J. Zlabinger, Ingrid Pabinger, Silvia Koder, Johannes Thaler, Cihan Ay, Florian Posch
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(1)
Purpose: Cancer patients are at an increased risk of venous thromboembolism (VTE). VEGF promotes the growth of highly thrombogenic tumor vessels. Here, we explored the utility of soluble plasma VEGF-A (sVEGF) as a biomarker for the prediction of VTE
Autor:
Michele G. Mehaffey, Seth M. Steinberg, Gini F. Fleming, Miguel A. Villalona-Calero, Jiuping Ji, Robert J. Kinders, P. Mickey Williams, William D. Walsh, David R. Gandara, James H. Doroshow, Peter M. Szabó, Ahrim Youn, Barbara A. Conley, Alice P. Chen, Daniel M. Sullivan, Richard M. Simon, Robert J. Morgan, Paul M. McGregor, Amit M. Oza, Michael Naughton, Shivaani Kummar, Chih Jian Lih, Deborah Allen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(7)
Purpose: Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial. To define the relative contribution of PARP inhibition to the observed clinic
Autor:
Christian Kollmannsberger, Ladan Fazli, S. Larry Goldenberg, Alan So, Michael Pollak, Martin E. Gleave, Kim N. Chi, Anna V. Tinker, Nevin Murray
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 18(12)
Purpose: Activation of the insulin-like growth factor 1 receptor (IGF-IR) is implicated in prostate cancer development and progression. This study evaluated biologic and clinical effects of figitumumab, a fully human monoclonal IGF-IR antibody, in pa
Autor:
Adil Al-Nahhas, Kaiyumars B. Contractor, Steve Hazell, Eric O. Aboagye, Paul Tadrous, Stephen Mangar, Giampaolo Tomasi, Laura M. Kenny, Giles Hellawell, Tara Barwick, Amarnath Challapalli, R. Charles Coombes, Paola Mapelli, Mathias Winkler
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(24)
Purpose: To evaluate the accuracy and biological basis for [11C]choline-PET-CT in the nodal staging of high risk localized prostate cancer patients. Experimental Design: Twenty-eight patients underwent dynamic [11C]choline-PET-CT of the pelvis and lo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(9)
Purpose: We examined whether nm23-H1 is a prognostic factor of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Experimental Design: We studied 102 consecutive, untreated PTCL-NOS patients from 1998 to 2008. The expression of nm23-H1 a